Compare Stocks → Move Your Money Before May 22 (From Stansberry Research) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NASDAQ:DCTHNASDAQ:GCTKNASDAQ:NMTC Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeDCTHDelcath Systems$5.42+3.0%$4.54$2.25▼$7.99$137.89M0.53222,641 shs83,973 shsGCTKGlucoTrack$0.45-1.7%$0.38$0.13▼$0.99$12.10M0.29183,959 shs139,387 shsNMTCNeuroOne Medical Technologies$1.14+2.3%$1.17$0.85▼$2.00$29.43M0.81177,834 shs52,264 shsElon Musk's Next MoveWondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceDCTHDelcath Systems-3.49%+12.03%+14.10%+18.47%-7.56%GCTKGlucoTrack-3.97%-31.34%+39.39%+109.09%-5.74%NMTCNeuroOne Medical Technologies-4.31%-2.63%-4.31%-10.48%-25.00%Move Your Money Before May 1 (Ad)Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? Click here to get the full story before May 1. MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationDCTHDelcath Systems3.9855 of 5 stars3.55.00.00.03.84.20.6GCTKGlucoTrack0.699 of 5 stars0.03.00.00.03.72.50.0NMTCNeuroOne Medical Technologies2.0024 of 5 stars3.55.00.00.02.20.00.0Analyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceDCTHDelcath Systems3.00Buy$18.50241.33% UpsideGCTKGlucoTrackN/AN/AN/AN/ANMTCNeuroOne Medical Technologies3.00Buy$2.2093.83% UpsideCurrent Analyst RatingsLatest NMTC, DCTH, and GCTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2024DCTHDelcath SystemsHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$18.00 ➝ $20.00(Data available from 4/26/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookDCTHDelcath Systems$2.07M66.61N/AN/A$0.72 per share7.53GCTKGlucoTrackN/AN/AN/AN/A$0.15 per shareN/ANMTCNeuroOne Medical Technologies$1.95M15.09N/AN/A$0.26 per share4.37Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateDCTHDelcath Systems-$47.68M-$2.97N/AN/AN/A-2,308.86%-563.60%-111.13%5/27/2024 (Estimated)GCTKGlucoTrack-$7.10M-$0.37N/A∞N/AN/A-172.38%-127.42%5/10/2024 (Estimated)NMTCNeuroOne Medical Technologies-$11.86M-$0.68N/A∞N/A-478.41%-267.82%-200.46%5/9/2024 (Estimated)Latest NMTC, DCTH, and GCTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails3/28/2024Q4 2023GCTKGlucoTrackN/A-$0.10-$0.10-$0.10N/AN/A3/26/2024Q4 23DCTHDelcath Systems-$0.67-$0.48+$0.19-$0.48$0.48 million$0.54 million 2/13/2024Q1 2024NMTCNeuroOne Medical TechnologiesN/A-$0.14-$0.14-$0.14N/A$0.98 million DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthDCTHDelcath SystemsN/AN/AN/AN/AN/AGCTKGlucoTrackN/AN/AN/AN/AN/ANMTCNeuroOne Medical TechnologiesN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioDCTHDelcath SystemsN/A2.262.06GCTKGlucoTrack0.063.223.22NMTCNeuroOne Medical TechnologiesN/A3.682.52OwnershipInstitutional OwnershipCompanyInstitutional OwnershipDCTHDelcath Systems61.12%GCTKGlucoTrack10.92%NMTCNeuroOne Medical Technologies16.07%Insider OwnershipCompanyInsider OwnershipDCTHDelcath Systems17.94%GCTKGlucoTrack17.70%NMTCNeuroOne Medical Technologies7.50%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableDCTHDelcath Systems7625.44 million20.88 millionOptionableGCTKGlucoTrack626.76 million22.02 millionNot OptionableNMTCNeuroOne Medical Technologies1625.93 million23.99 millionOptionableNMTC, DCTH, and GCTK HeadlinesSourceHeadlineNeuroOne® Announces First Implant of OneRF(TM) Ablation Electrodesstockhouse.com - April 11 at 2:46 PMNeuroOne® CEO Dave Rosa Featured on Bloomberg Technologyglobenewswire.com - April 10 at 9:00 AMNeuroOne implants first OneRF ablation electrodemassdevice.com - April 9 at 2:44 PMNeuroOne® Announces First Implant of OneRF™ Ablation Electrodesglobenewswire.com - April 9 at 9:05 AMNeuroOne® CEO Dave Rosa Featured on Fox Business Network’s Varney & Co.finance.yahoo.com - April 4 at 9:06 AMNeuroOne® CEO Dave Rosa Featured on Fox Business Network's Varney & Co.globenewswire.com - April 4 at 9:00 AMNeuroOne® Initiates Limited Commercial Launch of OneRF(TM) Ablation Systemstockhouse.com - March 28 at 3:16 PMNeuroOne begins neuroablation system launch in U.S.massdevice.com - March 27 at 11:04 AMNeuroOne® Initiates Limited Commercial Launch of OneRF™ Ablation Systemfinance.yahoo.com - March 26 at 10:19 AMNeuroone Medical Technologies Corp (NMTC)investing.com - March 22 at 11:04 PMNMTC Jul 2024 2.500 callca.finance.yahoo.com - March 17 at 8:55 PMNeuroOne® to Participate in the 36th Annual Roth Conferenceglobenewswire.com - March 8 at 12:00 PMNeuroOne Medical Technologies Corp: NeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)finanznachrichten.de - February 24 at 8:52 AMNeuroOne Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com - February 23 at 5:10 PMNeuroOne Medical Technologies Corp: NeuroOne Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Updatefinanznachrichten.de - February 16 at 11:11 AMNeuroOne Medical Technologies Corporation (NASDAQ:NMTC) Q1 2024 Earnings Call Transcriptfinance.yahoo.com - February 16 at 11:11 AMNeuroOne Medical Technologies Corporation (NMTC) Q1 2024 Earnings Call Transcriptseekingalpha.com - February 16 at 12:01 AMNeuroOne Medical Technologies Corporation Registered Shsmarkets.businessinsider.com - February 15 at 7:00 PMNeuroOne Medical Technologies First Quarter 2024 Earnings: Revenues Beat Expectations, EPS In Linefinance.yahoo.com - February 15 at 9:00 AMNeuroOne Medical Technologies GAAP EPS of -$0.14msn.com - February 13 at 5:02 PMNeuroOne® Reports First Quarter Fiscal Year 2024 Financial Results and Provides Corporate Updatefinance.yahoo.com - February 13 at 5:02 PMNeuroOne Medical Technologies earnings: here's what Wall Street expectsmarkets.businessinsider.com - February 12 at 3:57 PMNeuroOne® to Report First Quarter Fiscal Year 2024 Financial Results and Provide Corporate Update on February 13finance.yahoo.com - February 8 at 3:55 PMNeuroOne Medical Technologies Corp.wsj.com - January 24 at 1:05 AMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsDelcath SystemsNASDAQ:DCTHDelcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO is the FOCUS clinical trial for patients with metastatic hepatic dominant Uveal Melanoma to investigate objective response rate in metastatic uveal melanoma. It also provides HEPZATO as a stand-alone medical device under the CHEMOSAT Hepatic Delivery System trade name for Melphalan or CHEMOSAT for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.GlucoTrackNASDAQ:GCTKGlucoTrack, Inc., a medical device company, focuses on designing, developing, and commercializing non-invasive glucose monitoring devices for use by people with diabetes in the United States. It develops GlucoTrack, a non-invasive blood glucose monitor that helps people with diabetes and pre-diabetics to obtain blood glucose level readings without the pain. The company was formerly known as Integrity Applications, Inc. and changed its name to GlucoTrack, Inc. in November 2021. GlucoTrack, Inc. was founded in 2001 and is based in Or Yehuda, Israel.NeuroOne Medical TechnologiesNASDAQ:NMTCNeuroOne Medical Technologies Corporation operates as a medical technology company. The company focuses on the development and commercialization of thin film electrode technology for continuous electroencephalogram (cEEG) and stereoelectroencephalography (sEEG) recording, spinal cord stimulation, brain stimulation, and ablation solutions for patients suffering from epilepsy, Parkinson's disease, dystonia, essential tremors, chronic pain due to failed back surgeries, and other related neurological disorders. It has a strategic partnership with RBC Medical Innovations to develop a radio frequency ablation generator. The company was incorporated in 2009 and is based in Eden Prairie, Minnesota. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.